During the past decade, The Catholic University of Korea, Bucheon ST.Mary's Hospital conducted 53 clinical trials. In the 10-year time frame, 53 clinical trials started and 11 clinical trials were completed, i.e. on average, 20.8% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 9 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" #1 sponsor was "The Catholic University of Korea" with 10 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Seung-Jung Park" with 4 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 3 trials as a collaborator, "Daiichi Sankyo Korea Co., Ltd." with 3 trials as a collaborator, "Bucheon St. Mary's Hospital" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "The Catholic University of Korea" with 2 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" are "Stroke" (6 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Coronary Artery Disease" (4 trials), "Diabetes Mellitus, Type 2" (4 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" in a lesser frequency.

Most popular intervention types in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" are "Drug" (50 trials), "Device" (4 trials), "Biological" (3 trials), "Other" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Bismuth-Containing Quadruple Therapy" (2 trials), "Dapagliflozin 10mg" (2 trials), "Lanabecestat" (2 trials) and "Lansoprazole" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Catholic University of Korea, Bucheon ST.Mary's Hospital" are 74 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Catholic University of Korea, Bucheon ST.Mary's Hospital". undefined are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in The Catholic University of Korea, Bucheon ST.Mary's Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in The Catholic University of Korea, Bucheon ST.Mary's Hospital, 3 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 5 trials that are defined as “Not Applicable".